| Feature Type | Standardized | Nominal ANOVA | ||||
|---|---|---|---|---|---|---|
| mRNA | TL-2-105 | GDSC1000 | pan-cancer | AAC | 0.2 | 1e-08 |
| mRNA | Genentech Cpd 10 | GDSC1000 | pan-cancer | AAC | 0.16 | 2e-06 |
| mRNA | nelarabine | CTRPv2 | pan-cancer | AAC | 0.19 | 2e-06 |
| mRNA | XMD14-99 | GDSC1000 | pan-cancer | AAC | 0.17 | 2e-06 |
| mRNA | Nilotinib | GDSC1000 | pan-cancer | AAC | 0.19 | 2e-06 |
| mRNA | masitinib | GDSC1000 | pan-cancer | AAC | 0.16 | 5e-06 |
| mRNA | CH5424802 | GDSC1000 | pan-cancer | AAC | 0.17 | 8e-06 |
| mRNA | GSK1070916 | GDSC1000 | pan-cancer | AAC | 0.15 | 2e-05 |
| mRNA | carboplatin:etoposide (40:17 mol/mol) | CTRPv2 | pan-cancer | AAC | 0.12 | 6e-05 |
| mRNA | Nilotinib | CCLE | pan-cancer | AAC | 0.21 | 8e-05 |